Related Experiment Video

Updated: May 30, 2026

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

Her-2/neu gene amplification and over-expression in stomach and esophageal adenocarcinoma: from pathology to

Judith Maresch1, Sebastian F Schoppmann, Christiane M R Thallinger

  • 1Department of Pathology, General Hospital - Medical University of Vienna, Austria.

Critical Reviews in Oncology/Hematology
|July 26, 2011
PubMed

Insights

Over-expression of Her-2/neu in stomach and esophageal cancers drives targeted therapies. This review covers Her-2/neu diagnosis, inhibition, toxicity, and resistance in adenocarcinoma.

Area of Science:

  • Oncology
  • Molecular Biology
  • Gastroenterology

Background:

  • Her-2/neu (Human Epidermal growth factor Receptor 2) over-expression and gene amplification are key drivers in stomach and esophageal cancers.
  • This discovery has led to the development of targeted therapies specifically aimed at the Her-2/neu protein.

Purpose of the Study:

  • To review the current diagnostic methods for Her-2/neu over-expression and amplification.
  • To discuss the therapeutic strategies involving Her-2/neu inhibition.
  • To examine treatment-related toxicity and the emergence of resistance to Her-2/neu-targeted therapies in gastric and esophageal adenocarcinoma.

Main Methods:

  • Literature review of studies and clinical trials on Her-2/neu in stomach and esophageal adenocarcinoma.
  • Synthesis of current data on diagnostic techniques, therapeutic approaches, toxicity profiles, and resistance mechanisms.

Main Results:

  • Established diagnostic approaches for identifying Her-2/neu over-expression and amplification.
  • Overview of targeted treatment options and their associated toxicities.
  • Identification of Her-2/neu resistance as a significant challenge in treatment efficacy.

Conclusions:

  • Her-2/neu status is critical for guiding treatment decisions in specific gastrointestinal adenocarcinomas.
  • Targeted therapy offers a promising avenue, but managing toxicity and overcoming resistance are paramount for improving patient outcomes.

More Related Videos

Building Up a High-throughput Screening Platform to Assess the Heterogeneity of HER2 Gene Amplification in Breast Cancers11:34

Building Up a High-throughput Screening Platform to Assess the Heterogeneity of HER2 Gene Amplification in Breast Cancers

Published on: December 5, 2017

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT10:28

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT

Published on: January 22, 2018

Related Concept Videos

Barrett Esophagus-II: Clinical Manifestations and Management01:21

Barrett Esophagus-II: Clinical Manifestations and Management

Individuals with Barrett's esophagus are often asymptomatic, but they may experience symptoms commonly associated with GERD, such as heartburn and acid regurgitation. Additional symptoms can include difficulty swallowing, chest pain, unintentional weight loss, blood in the stool (which may appear black, tarry, or bloody), and episodes of vomiting.
To diagnose Barrett's esophagus, healthcare providers often recommend an endoscopy for those showing symptoms of acid reflux. The procedure entails...
Gastritis II: Pathophysiology01:26

Gastritis II: Pathophysiology

The pathophysiology of gastritis begins with the colonization of the stomach lining by Helicobacter pylori (H. pylori). This bacterium spreads mainly via the oral-oral route through saliva or shared utensils, and can also be transmitted in overcrowded or unhygienic environments through contaminated water, despite its brief survival outside the body.ColonizationOnce ingested, H. pylori enters the stomach and begins colonization by navigating through the mucus layer lining the stomach wall. It...
Barrett Esophagus-I: Introduction01:21

Barrett Esophagus-I: Introduction

Barrett's esophagus is a medical condition where the esophageal mucosa is significantly damaged by stomach acid or other digestive fluids, often due to long-term exposure associated with gastroesophageal reflux disease (GERD). In GERD, a weakened or abnormally relaxed lower esophageal sphincter allows stomach acid to flow persistently into the esophagus.
This constant acid exposure transforms the esophagus's pink mucosal lining (stratified squamous epithelium) into a type of lining more similar...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...